MAPT and Cognitive impairment: Gastrodin and Gastrodigenin (25 and 50 mg/kg, po for 4 weeks) improved the cognitive impairment of 2VO rats by reducing the expression of Aβ and inhibiting the phosphorylation of Tau protein.